DEA Proposes Permanent Schedule I Ban for Tianeptine, the Original 'Gas Station Heroin'
核心洞察
The DEA moved on July 8 to permanently classify tianeptine as a Schedule I controlled substance, citing high abuse potential and serious harm including fatal overdoses.
Tianeptine is approved abroad as an atypical tricyclic antidepressant at low doses but acts as an opioid receptor agonist at the high doses found in unregulated products.
U.S. poison center data show tianeptine exposures rose approximately 1,400% between 2015 and 2023, with 52% of single-substance exposures producing moderate effects and 12% major effects.
The Drug Enforcement Administration (搜索) formally proposed on July 8 to permanently ban tianeptine under Schedule I of the Controlled Substances Act, marking a decisive federal response to a substance that has come to epitomize the broader phenomenon of unregulated "gas station drugs." The agency is accepting public comment, including requests for a hearing, through August 7.
Tianeptine is approved in several countries as an atypical tricyclic antidepressant, but at the doses consumed in over-the-counter products sold at convenience stores and gas stations, its pharmacology shifts dramatically. "Users are ingesting tianeptine in high dosages for its opioid effects, resulting in serious harm, including fatal overdoses both in combination with other opioids and with tianeptine alone," the DEA stated in its proposal. The Department of Health and Human Services concluded that tianeptine has a high potential for abuse, and the DEA subsequently completed the eight-factor analysis required for permanent scheduling.
Clinical Pharmacology and the Dose-Dependent Divide
At therapeutic doses — 12.5 mg taken three times daily — tianeptine modulates glutamatergic signaling and exhibits only weak mu-opioid receptor (搜索) activity. However, products sold under brand names such as Zaza, Tianaa, Neptune's Fix, and Pegasus contain hundreds of milligrams per dose, taken multiple times daily. At those levels, the opioid activity becomes the dominant pharmacological effect. The drug's short half-life of approximately 2.5 hours drives a characteristic addiction pattern: users redose every few hours, often through the night, and escalate rapidly.
The DEA reviewed clinical studies supporting tianeptine's use as a prescription medication abroad but determined these could not be factored into assessments of abuse potential because therapeutic doses are far lower than what is reported by users of unregulated formulations.
Poison Center Data and Adverse Outcomes
An analysis of 892 single-substance tianeptine exposures reported to U.S. poison centers between 2015 and 2023 revealed a troubling safety profile: 52% produced moderate effects and 12% produced major effects. Forty percent required medical admission and 23% required intensive care unit admission. Documented adverse effects include respiratory depression, seizures, loss of consciousness, tachycardia, and agitation. Withdrawal can be severe enough to necessitate inpatient care.
Exposure trends underscore the escalating public health concern. Tianeptine exposures rose approximately 1,400% between 2015 and 2023, including a 525% increase from 2018 to 2023 alone. At least fifteen states have independently banned or scheduled tianeptine while federal action remained pending.
Adulteration Compounds the Risk
In late 2023, the Food and Drug Administration (搜索) issued a public safety alert for Neptune's Fix, one of the more prominent tianeptine products. It had been linked to a string of non-fatal exposures reported to New Jersey poison control, and laboratory analysis of some samples revealed synthetic cannabinoids (搜索) not listed among the ingredients. A Centers for Disease Control and Prevention report associated those substances with unexpected symptoms, warning that health care workers and the public should "be aware that readily purchased tianeptine products might be adulterated with synthetic cannabinoid receptor agonists or other drugs and can produce severe adverse effects."
Neptune's Fix was voluntarily recalled by distributors in early 2024. The FDA formally attributed the recall to "undeclared tianeptine," though the product's packaging had advertised it as a tianeptine formulation.
Fatal Overdose Reports
The DEA cited fatal overdoses in its scheduling proposal, though the circumstances surrounding these deaths vary. For a Pennsylvania overdose that represents the agency's sole example of a death attributed to tianeptine alone, the DEA noted that a "digital scale with a white powdery substance and other paraphernalia were located on the nightstand next to the bed." A more recent fatal overdose, also in Pennsylvania, was attributed "strictly due to" tianeptine, though the formulation was unknown.
A 2024 report from the Center for Forensic Science Research & Education suggested that tianeptine is not being mixed into the unregulated fentanyl supply, and it has not been widely linked to fatal overdose despite the DEA and FDA framing.
Regulatory Pathway and Legislative Context
The DEA requested that HHS review tianeptine nearly three years ago, under the Biden administration. HHS recommended Schedule I placement in July 2025. In 2024, Congress introduced a proposal to add tianeptine to the CSA under Schedule III rather than Schedule I, but that legislation did not advance.
The DEA opted for permanent scheduling rather than the more common temporary scheduling process, which bypasses HHS review and the possibility of judicial review. Permanent scheduling is lengthier but provides a more durable regulatory framework.
Not mentioned in the DEA's proposal is that between 2021 and 2023, the FDA was considering an investigational new drug application for a tianeptine medication. The compound was in Phase 2 trials as a treatment for depression and post-traumatic stress disorder before being dropped for ineffectiveness.
The Broader Gas Station Drug Landscape
"Amidst the current opioid epidemic, users are constantly searching out new substances, with often similar or increased danger to the user, to feed their addiction," the DEA stated. "In addition, some users have attempted to self-medicate using online drugs such as tianeptine, marketed as 'addiction remedies.' While some users seek out substances to curb withdrawal symptoms from other opioids, select individuals try new substances to gain a novel high from the substance or to evade drug tests that more commonly known substances trigger."
Tianeptine sits within an expanding category of unregulated products that includes 7-OH, kratom, Delta-8 THC, and an evolving list of synthetic opioids, cannabinoids, and cathinones. Under the 1994 Dietary Supplement Health and Education Act, supplements built from ingredients presumed safe require no pre-market approval, allowing companies to formulate products, print labels, and ship them without prior FDA review. The agency's authority is retrospective, acting only after harm surfaces.